| Literature DB >> 35974927 |
Mohammad Reza Hatamnejad1,2, Hamed Bazrafshan3,2, Morteza Hosseinpour1,2, Peyman Izadpanah3,2, Mohammad Reza Kasravi4, Mehdi Bazrafshan1.
Abstract
Background: Ventricular repolarization measurement by QTc interval and QT dispersion can recognize high-risk patients. Previous research tended to evaluate the act of repolarization indicators alone but this study aimed to elucidate their prognostic utility before and after modifying confounding parameters in risk stratification of different aspects of prognosis in decompensated heart failure patients with systolic dysfunction.Entities:
Keywords: Decompensated heart failure; QT dispersion; QTc interval; Ventricular systolic dysfunction
Year: 2022 PMID: 35974927 PMCID: PMC9348206 DOI: 10.22088/cjim.13.3.533
Source DB: PubMed Journal: Caspian J Intern Med ISSN: 2008-6164
Figure 1Flowchart of patient selection. Among the 858 patients who were admitted to the emergency department with the primary diagnosis of acute heart failure, 369 were eligible for the study. Two hundred four patients were excluded. Thus, data of 165 patients were analyzed
Baseline characteristics of patients
| Patient characteristics | Patients |
|---|---|
| CK-MB (IU/L) | 22 ± 24 |
| Age at admission (years) | 65 ± 14.1 |
| Male/Female | 58/42 % |
| Current smoker | 32.1 % |
| Substance user | 32.7 % |
| Body mass index (kg/m2) | 25.1 ± 4.7 |
| NYHA Classification | |
| NYHA III | 50.3% |
| NYHA IV | 49.7% |
| Ejection fraction (%) | 23.8 ± 8.5 % |
|
| |
| Fatigue | 12.1 % |
| Dyspnea | 97.6 % |
| Cough | 19.4 % |
| Dyspnea on exertion | 87.3 % |
| Orthopnea | 55.2 % |
| Paroxysmal nocturnal dyspnea | 15.2 % |
| Nocturia | 4.2 % |
| Weight loss | 3.6 % |
| Weight gain | 6.1 % |
| Peripheral edema | 46.1 % |
| Loss of appetite | 17.1 % |
| Cheyne-stokes respiration | 3 % |
|
| |
| Tachycardia(>100/min) | 23 % |
| Thready pulse | 6.7 % |
| Tacypnea(>20/min) | 9.1 % |
| Cooled or mottled extremities | 12.1 % |
| Elevated JVP | 14.5 % |
| Dullness or diminished breath sound in one or both lungs | 52.7 % |
| Rales/Wheeze sound | 71.5 % |
| Third or fourth heart sound | 43.6 % |
| Tricuspid or mitral regurgitation murmur | 53.9 % |
| Hepatomegaly | 3 % |
| Ascites | 13.9 % |
| Anasarca | 9.1 % |
|
| |
| Systolic blood pressure (mm Hg) | 129 ± 27 |
| Diastolic blood pressure (mm Hg) | 80 ± 15 |
| Heart rate (per minute) | 90 ± 18 |
| Temperature °C | 36.7 ± 0.45 |
| Oxygen saturation (%) | 92.6 ± 6.3 |
|
| |
| Diabetes mellitus | 44.2 % |
| Controlled | 36.6 % |
| Uncontrolled | 63.4 % |
| Hypertension | 63.6 % |
| Controlled | 53.3 % |
| Uncontrolled | 46.7 % |
| Hyperlipidemia | 61.8 % |
| Anemia | 60 % |
| Thalassemia major | 2.4 % |
| Hyperthyroidism | 2.4 % |
| Hypothyroidism | 7.3 % |
| Severe renal impairment | 19.4 % |
| Cerebrovascular disease | 8.5 % |
| Liver disease | 3.6 % |
| Obstructive pulmonary disease (Asthma/COPD) | 9.7 % |
| Previous coronary artery disease | 69.1 % |
| Coronary revascularization | 57.9 % |
|
| |
| Hypertension | 14.6 % |
| Valvular heart disease | 7.2 % |
| Ischemic heart disease | 69.1 % |
| Dilated cardiomyopathy | 9.1 % |
|
| |
| Heart rate (bpm) | 90 ± 18 |
| QRS duration (ms) | 101 ± 11 |
| QT interval duration (ms) | 368 ± 34 |
| QTc interval duration (ms) | 440 ± 31.3 |
| QT dispersion (ms) | 46 ± 21.6 |
|
| |
| Arrhythmic events | 33.9 % |
| Ventricular premature contraction | 28.4 % |
| Ventricular tachycardia | 7.8 % |
| Ventricular fibrillation | 5.4 % |
|
| |
| Pleural effusion | 80 % |
| Heart enlargement | 62.5 % |
| Calcified plaque (in the aortic arch or descending aorta) | 24.1 % |
| Pulmonary edema | 13.8 % |
| Pulmonary nodular infiltration | 3.4 % |
| Pulmonary patchy infiltration | 52.4 % |
|
| |
| Troponin I (Mic gr/L) | 0.14 ± 0.1 |
| White cell blood count (10^3/µL) | 8.3 ± 3.4 |
| Hemoglobin (g/dL) | 12 ± 2.2 |
| Platelet count (10^3/µL) | 201 ± 75 |
| Prothrombin time (sec) | 15.7 ± 5.6 |
| Partial thrombin time (sec) | 36.7 ± 12 |
| INR (Index) | 1.6 ± 1.8 |
| Random blood sugar (mg/dL) | 149 ± 80 |
| Sodium (mEq/dL) | 137 ± 4 |
| Potassium (mEq/dL) | 4.3 ± 0.5 |
| Blood urea nitrogen (mg/dL) | 30 ± 18 |
| Creatinine (mg/dL) | 1.5 ± 1 |
| SGOT (mg/dL) | 108 ± 507 |
| SGPT (IU/L) | 99 ± 460 |
| Alkaline phosphatase (mg/dL) | 252 ± 130 |
| Albumin (mg/dL) | 3.8 ± 0.45 |
| Globulin (g/dL) | 2.6 ± 0.6 |
| Total protein (g/dL) | 6.3 ± 0.74 |
| Total bilirubin (mg/dL) | 1.5 ± 1.5 |
| Direct bilirubin (mg/dL) | 0.62 ± 0.83 |
| Triglyceride (mg/dL) | 118 ± 59 |
| Cholesterol (mg/dL) | 142 ± 44 |
| HDL-CH (mg/dL) | 38 ± 14.8 |
| LDL-C (mg/dL) | 91 ± 77.5 |
| Uric acid (mg/dL) | 8.5 ± 2.9 |
NYHA, New York Heart Association classification; JVP, Jugular venous pulse; COPD, Chronic obstructive pulmonary disease; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass grafting; INR, International normalized ratio; SGOT, Serum glutamic-oxaloacetic transaminase; SGPT, Serum glutamic-pyruvic transaminase; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; CK-MB, creatine kinase-myoglobin binding. Binary variables are expressed by percentage; continuous variables are illustrated as mean ± standard deviation
Medications that have been used before admission and during hospitalization
| Medication | Before admission(%) | Hospital course(%) |
|---|---|---|
| Catecholamine | 0% | 7.3% |
| Anti-platelet | 66.7% | 79.4% |
| Anti-coagulant | 30.9% | 67.9% |
| ACE inhibitor | 21.8% | 37.6% |
| ARB | 35.8% | 30.3% |
| Calcium channel blocker | 12.1% | 12.7% |
| ß-Blocking agent | 64.8% | 83% |
| Loop diuretics | 58.8% | 93.9% |
| Thiazide diuretics | 3% | 4.2% |
| Potassium-sparing diuretics | 41.8% | 56.4% |
| Statins | 52.7% | 72.7% |
| Fibrates | 2.4% | 0% |
| Oral antidiabetic drugs | 17.6% | 12.1% |
| Insulin | 12.1% | 17.6% |
| Digitalis | 17.6% | 30.9% |
| Nitrates | 43% | 64.8% |
| Allopurinol | 3% | 6.1% |
ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker.
Descriptive statistics of patients’ outcome follow-up
| Outcome | Patients(%) |
|---|---|
| Times of Follow up (days) | 181 ± 56 |
| Hospitalization course (days) | 5 ± 3 |
| Survivors | 83% |
| In-hospital mortality | 7.3% |
| All-cause long-term mortality | 9.7% |
| Sudden death | 37.5% |
| Progression of heart failure | 37.5% |
| Non-cardiac death | 25% |
| Other cardiac cause | 0% |
The outcome of the patients are presented as (%) or mean±SD of patients
Statistically significant univariate predictors of arrhythmic events and in-hospital mortality (mean±SD or the percentage of the population)
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| Peripheral edema a | 53.6% | 42.2% | 0.165 | 81.8% | 43.5% | 0.014 |
| Thready pulse a | 14.3% | 2.8% | 0.008 | 27.3% | 5.2% | 0.027 |
| Elevated JVP a | 14.3% | 14.7% | 0.946 | 45.5% | 12.3% | 0.011 |
| Cooled or mottled extremity a | 19.6% | 8.3% | 0.034 | 27.3% | 11% | 0.111 |
| Hepatomegaly a | 8.9% | 0% | 0.004 | 9.1% | 2.6% | 0.295 |
| Ascites a | 26.8% | 7.3% | 0.034 | 36.4% | 12.3% | 0.049 |
| Anasarca a | 21.4% | 2.8% | P<0.001 | 36.4% | 7.1% | 0.010 |
| Past history of anemia a | 63.2% | 58.3% | 0.547 | 90.9% | 57.8% | 0.049 |
| Past history of renal disease a | 26.3% | 15.7% | 0.102 | 63.6% | 16.2% | 0.001 |
| Past drug history of insulin a | 19.3% | 8.3% | 0.040 | 27.3% | 11% | 0.111 |
| ß-Blocking agent treatment a | 91.2% | 78.8% | 0.042 | 81.8% | 83.1% | 0.912 |
| Thiazide diuretics treatment a | 5.3% | 3.7% | 0.694 | 18.12% | 3.2% | 0.018 |
| Insulin treatment a | 19.3% | 16.7% | 0.673 | 45.5% | 15.6% | 0.026 |
| Allopurinol treatment a | 10.5% | 3.7% | 0.081 | 27.3% | 4.5% | 0.021 |
| Heart rate (bpm) b | 91.77 ± 20.9 | 87.06 ± 15.48 | 0.006 | 92.55 ± 23.01 | 90.4± 17.8 | 0.852 |
| QRS duration (sec) b | 104.3 ± 9.21 | 99.4 ± 11.6 | 0.013 | 104.8 ± 8.2 | 100.8 ± 11.2 | 0.338 |
| QTc interval (ms) b | 465.3 ± 25.8 | 424.9 ± 19.3 | P<0.001 | 490 ± 14.9 | 431.1 ± 26.2 | P<0.001 |
| QT dispersion (ms) b | 66.67 ± 23.6 | 36.5 ± 13.09 | P<0.001 | 86.36 ± 14.8 | 44.16 ± 20.2 | P<0.001 |
| Ejection fraction (%) b | 21.23 ± 8.82 | 25.28 ± 7.95 | 0.004 | 19.09 ± 8.3 | 24.22 ± 8.3 | 0.064 |
| Hemoglobin (g/dL) b | 11.7 ± 2.67 | 12.15 ± 1.91 | 0.329 | 10.2 ± 2.1 | 12.1 ± 2.1 | 0.009 |
| Prothrombin time (sec) b | 17.1 ± 8.2 | 14.9 ± 3.34 | 0.034 | 18.2 ± 5.7 | 15.5 ± 5.5 | 0.047 |
| Sodium (mg/dL) b | 137 ± 5.6 | 138.4 ± 4.02 | 0.257 | 133.3 ± 8.7 | 138.2 ± 4.1 | 0.015 |
| Potassium (mg/dL) b | 4.39 ± 0.53 | 4.28 ± 0.54 | 0.279 | 4.82 ± 0.86 | 4.28 ± 0.49 | 0.048 |
| BUN (mg/dL) b | 34.58 ± 21.05 | 28.14 ± 16.58 | 0.57 | 48.8 ± 26.1 | 29.05 ± 17.1 | 0.013 |
| Creatinine (mg/dL) b | 1.5 ± 0.82 | 1.51 ± 1.09 | 0.481 | 1.48 ± 1.01 | 1.91 ± 0.81 | 0.007 |
| SGOT (mg/dL) b | 276.6 ± 900.5 | 31.74 ± 30.5 | 0.063 | 1004 ± 1763 | 32.3 ± 29.7 | 0.003 |
| SGPT (mg/dL) b | 245 ± 819 | 32.8 ± 29.6 | 0.144 | 870 ± 1630 | 33.8 ± 28.1 | 0.049 |
| Cholesterol (mg/dL) b | 130.8 ± 34.7 | 150.2 ± 48 | 0.063 | 104 ± 43.4 | 146 ± 43 | 0.013 |
| HDL (mg/dL) b | 33 ± 7.8 | 40.4 ± 17 | 0.083 | 38 ± 14.8 | 104 ± 43.4 | 0.028 |
| Uric acid (U/L) b | 10.6 ± 3.5 | 7.53 ± 2.06 | 0.002 | 14.1 ± 3.6 | 7.84 ± 2.04 | 0.037 |
All statistically significant p-values (p < 0.05) are in bold. For abbreviations see Table 1.
a Statistical significance of the chi-square test. b Statistical significance of Man Whitney u test (only for uric acid, student’s t-test was used)
b Mean rank was compared between patients both with and without given characteristics in Man Whitney u test, nevertheless arrhythmic mean was applied for report
Multivariate analysis of significant predictors of arrhythmic events and in-hospital mortality
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| QTc interval (ms) | 1.085 ( 1.023 ; 1.151 ) | 0.007 | 1.116 ( 1.028 ; 1.211) | 0.009 |
| QT dispersion (ms) | 1.077 ( 1.020 ; 1.137 ) | 0.007 | 1.067 ( 1.015 ; 1.123 ) | 0.011 |
| Past history of anemia | 1.320 ( 1.057 ; 1.675 ) | 0.635 | 1.551 ( 1.373 ; 1.776 ) | 0.036 |
All statistically significant p-values (p<0.05) are in bold
1 Statistical significance of odds ratio
2 Odds ratio calculated by multivariate logistic regression for arrhythmia and in-hospital mortality and its 95 % confidence interval
Univariate and multivariate analysis of significant predictors of all-cause and sudden death mortality
|
|
| |||
|---|---|---|---|---|
|
|
|
| ||
|
|
|
|
| |
| Age | 1.011 ( 0.974 ; 1.050 ) | 0.567 | 1.092 ( 1.006 ; 1.185 ) | 0.034 |
| Smoking | 0.363 ( 0.135 ; 0.976 ) | 0.045 | 0.241 ( 0.044 ; 1.316 ) | 0.100 |
| Weight gain | 0.262 ( 0.074 ; 0.925 ) | 0.037 | 0.318 ( 0.037 ; 2.738 ) | 0.297 |
| Anasarca | 0.261 ( 0.073 ; 0.931 ) | 0.038 | 0.134 ( 0.024 ; 0.759 ) | 0.023 |
| Diabetes mellitus | 0.271 ( 0.094 ; 0.785 ) | 0.016 | 1.237 ( 0.225 ; 6.817 ) | 0.807 |
| Hypertension | 1.731 ( 0.649 ; 3.013 ) | 0.273 | 1.291 ( 1.046 ; 1.593 ) | 0.050 |
| Hyperthyroidism | 0.110 ( 0.025 ; 0.493 ) | 0.004 | 0.088 ( 0.010 ; 0.776 ) | 0.029 |
| QRS duration (ms) | 1.011 ( 0.967 ; 1.058 ) | 0.622 | 1.015 ( 0.942 ; 1.094 ) | 0.696 |
| QTc interval (ms) | 1.018 ( 1.005 ; 1.031 ) | 0.005 | 1.032 ( 1.014 ; 1.050 ) | P<0.001 |
| QT dispersion (ms) | 1.002 ( 0.980 ; 1.022 ) | 0.891 | 1.015 ( 0.989 ; 1.042 ) | 0.253 |
| Random blood sugar | 1.004 ( 1.000 ; 1.009 ) | 0.034 | 0.995 ( 0.982 ; 1.009 ) | 0.482 |
| Multivariate analysis of | All-cause | Sudden death | ||
| Significant predictors | HR (95 % CI) 2 |
| HR (95 % CI) 2 |
|
| Age | 1.029 ( 0.019 ; 1.076 ) | 0.215 | 1.106 ( 1.025 ; 1.194 ) | 0.010 |
| Smoking | 0.280 ( 0.091 ; 0.858 ) | 0.026 | 0.101 ( 0.014 ; 0.744 ) | 0.124 |
| Weight gain | 0.116 ( 0.019 ; 0.705 ) | 0.019 | 0.442 ( 0.328 ; 0.597 ) | 0.690 |
| Anasarca | 0.282 ( 0.053 ; 1.493 ) | 0.137 | 0.132 ( 0.014 ; 1.232 ) | 0.076 |
| Diabetes mellitus | 0.212 ( 0.053 ; 0.856 ) | 0.029 | 0.771 ( 0.605 ; 0.981 ) | 0.067 |
| Hypertension | 1.187 ( 0.533 ; 1.841 ) | 0.311 | 1.347 ( 1.043 ; 1.671 ) | 0.550 |
| Hyperthyroidism | 0.019 ( 0.002 ; 0.165 ) | P<0.001 | 0.162 ( 0.003 ; 0.497 ) | 0.385 |
| QRS duration (ms) | 1.014 ( 0.954 ; 1.077 ) | 0.659 | 0.926 ( 0.791 ; 1.084 ) | 0.340 |
| QTc interval (ms) | 1.041 ( 1.015 ; 1.067 ) | 0.002 | 1.063 ( 1.023 ; 1.105 ) | 0.002 |
| QT dispersion (ms) | 1.012 ( 0.990 ; 1.034 ) | 0.782 | 1.018 ( 0.941 ; 1.055 ) | 0.192 |
| Random blood sugar | 1.005 ( 0.999 ; 1.012 ) | 0.119 | 0.997 ( 0.970 ; 1.026 ) | 0.846 |
All statistically significant p-values (p<0.05) are in bold 1 Statistical significance of hazard ratio 2 Hazard ratio calculated by multivariate Cox proportional hazard regression for long-term mortality and its 95 % confidence interval
Figure 2Kaplan-Meier curves for survival compartment